AAL

Analyst: This Pharma Stock Could Double After FDA Nod

Evolus stock has already surged 20% out of the gate today

Feb 4, 2019 at 10:08 AM
facebook X logo linkedin


The shares of pharmaceutical concern Evolus Inc (NASDAQ:EOLS) are soaring this morning, after the Food and Drug Administration (FDA) late Friday approved the company's Jeuveau to treat frown lines. The regulatory body back in May declined to approve the Botox rival, but accepted a resubmitted marketing application in August. Out of the gate today, EOLS stock is up 20% to trade at $22, extending Friday's late-session rally.

Cantor Fitzgerald weighed in on EOLS, saying the FDA approval "underscores our positive investment thesis on the stock," which was named one of the brokerage firm's top ideas for 2019. Further, Cantor thinks Wall Street "may be underestimating how quick the uptake of Jeuveau could be," and reiterated an "overweight" rating and $35 price target -- nearly double the equity's close of $18.33 on Friday.

Since touching a near-term bottom of $10.22 on Dec. 24, Evolus stock has more than doubled on the charts, and on Friday topped its 200-day moving average for the first time ever. The security could now face off against the $24 level, which is double EOLS' initial public offering (IPO) price almost one year ago.

A short squeeze could help propel EOLS even higher, though. Short interest on the biotech surged 59% in the past two reporting periods, and now represents 18.4% of the equity's total available float. At the stock's average pace of trading, it would take more than a week to buy back these bearish bets.

 

 

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.